Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?

European Journal of Cancer

Volumn 48, Issue 14, 2012, Pages 2146-2154

  Tropé, Claes G ^a,b   Elstrand, Mari B ^c   Sandstad, Berit ^a   Davidson, Ben ^b,d   Oksefjell, Halldis ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c VESTRE VIKEN HOSPITAL TRUST   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chemotherapy; Ovarian carcinoma; Population based analysis; Surgery; Survival

Indexed keywords

PACLITAXEL; PLATINUM;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; NORWAY; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865496961     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.031     Document Type: Article

References (29)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
2. A.P. Heintz, F. Odicino, and P. Maisonneuve Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer Int J Gynaecol Obstet 95 Suppl. 1 2006 S161 S192
3. G.D. Aletti, S.C. Dowdy, K.C. Podratz, and W.A. Cliby Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system Gynecol Oncol 105 2007 84 89
4. C.T. Griffiths Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl Cancer Inst Monogr 42 1975 101 104
5. A.R. Munkarah, A.V. Hallum 3rd, and M. Morris Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer Gynecol Oncol 64 1997 13 17
6. J.P. Curtin, R. Malik, E.S. Venkatraman, R.R. Barakat, and W.J. Hoskins Stage IV ovarian cancer: impact of surgical debulking Gynecol Oncol 64 1997 9 12
7. P.C. Liu, I. Benjamin, and M.A. Morgan Effect of surgical debulking on survival in stage IV ovarian cancer Gynecol Oncol 64 1997 4 8
8. J.I. Akahira, H. Yoshikawa, and Y. Shimizu Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study Gynecol Oncol 81 2001 398 403
9. R.E. Bristow, F.J. Montz, L.D. Lagasse, R.S. Leuchter, and B.Y. Karlan Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer Gynecol Oncol 72 1999 278 287
10. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Suvival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
11. W.E. Winter 3rd, G.L. Maxwell, and C. Tian Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 26 2008 83 89
12. P. Wimberger, M. Wehling, and N. Lehmann Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group) Ann Surg Oncol 17 2010 1642 1648
13. E.L. Eisenhauer, N.R. Abu-Rustum, and Y. Sonoda The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer Gynecol Oncol 108 2008 276 281
14. P.E. Schwartz, J.T. Chambers, and R. Makuch Neoadjuvant chemotherapy for advanced ovarian cancer Gynecol Oncol 53 1994 33 37
15. M.E. van der Burg, M. van Lent, and M. Buyse The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer N Engl J Med 332 1995 629 634
16. I. Vergote, T. van Gorp, F. Amant, P. Neven, and P. Berteloot Neoadjuvant chemotherapy for ovarian cancer Oncology (Williston Park) 19 2005 1615 1622
17. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 2009 2315 2320
18. I. Vergote, C.G. Tropé, and F. Amant Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
19. P.G. Rose, S. Nerenstone, and M.F. Brady Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 351 2004 2489 2497
20. R.E. Bristow, E.L. Eisenhauer, A. Santillan, and D.S. Chi Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction Gynecol Oncol 104 2007 480 490
21. S. Tangjitgamol, S. Manusirivithaya, M. Laopaiboon, and P. Lumbiganon Interval debulking surgery for advanced epithelial ovarian cancer Cochrane Database Syst Rev 2 2009 CD006014
22. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol Oncol 103 2006 1070 1076
23. A. du Bois, A. Reuss, and E. Pujade-Lauraine Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomised phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
24. I. Vergote, I. De Wever, and W. Tjalma Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol Oncol 71 1998 431 436
25. S. Memarzadeh, S.B. Lee, J.S. Berek, and R. Farias-Eisner CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer Int J Gynecol Cancer 13 2003 120 124
26. S. Risum, C. Høgdall, and A. Loft Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography - a prospective study Gynecol Oncol 108 2008 265 270
27. I. Vergote, S. Marquette, F. Amant, P. Berteloot, and P. Neven Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma Int J Gynecol Cancer 15 2005 776 779
28. I. Vergote, F. Amant, and G. Kristensen Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer Eur J Cancer 47 Suppl. 3 2011 S88 S92
29. M.M. Thrall, H.J. Gray, and R.G. Symons Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer Gynecol Oncol 123 2011 461 466